Pharmacoeconomics

Papers
(The H4-Index of Pharmacoeconomics is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)271
A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)183
Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018102
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment80
International Valuation Protocol for the EQ-5D-Y-3L78
A Comparison of the EQ-5D-3L and EQ-5D-5L64
An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis58
Calculating and Interpreting ICERs and Net Benefit56
What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study48
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach45
Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States45
The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy Makers43
EQ-5D-Y Value Set for Slovenia42
Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment37
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations37
Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates31
Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines31
Why it’s Time to Abandon the ICER30
Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers28
Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review26
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness25
Economic Evaluation of Digital Health Interventions: Methodological Issues and Recommendations for Practice25
Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review24
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension24
0.033370018005371